

# Hypermethylation of the Inactive X Chromosome Is a Frequent Event in Cancer

Natalie Jäger,<sup>1</sup> Matthias Schlesner,<sup>1</sup> David T.W. Jones,<sup>2</sup> Simon Raffel,<sup>3,4</sup> Jan-Philipp Mallm,<sup>5</sup> Kristin M. Junge,<sup>6</sup> Dieter Weichenhan,<sup>7</sup> Tobias Bauer,<sup>1</sup> Naveed Ishaque,<sup>1,21</sup> Marcel Kool,<sup>2</sup> Paul A. Northcott,<sup>2</sup> Andrey Korshunov,<sup>8,9</sup> Ruben M. Drews,<sup>1</sup> Jan Koster,<sup>10</sup> Rogier Versteeg,<sup>10</sup> Julia Richter,<sup>11</sup> Michael Hummel,<sup>12</sup> Stephen C. Mack,<sup>13</sup> Michael D. Taylor,<sup>13</sup> Hendrik Witt,<sup>2,14</sup> Benedict Swartman,<sup>15</sup> Dietrich Schulte-Bockholt,<sup>15</sup> Marc Sultan,<sup>16</sup> Marie-Laure Yaspo,<sup>16</sup> Hans Lehrach,<sup>16</sup> Barbara Hutter,<sup>1</sup> Benedikt Brors,<sup>1</sup> Stephan Wolf,<sup>17</sup> Christoph Plass,<sup>7</sup> Reiner Siebert,<sup>11</sup> Andreas Trumpp,<sup>3,4,18</sup> Karsten Rippe,<sup>5</sup> Irina Lehmann,<sup>6</sup> Peter Lichter,<sup>18,19,21</sup> Stefan M. Pfister,<sup>2,14,18</sup> and Roland Eils<sup>1,20,21,\*</sup>

<sup>1</sup>Division of Theoretical Bioinformatics

<sup>2</sup>Division of Pediatric Neurooncology

<sup>3</sup>Division of Stem Cells and Cancer

German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

<sup>4</sup>Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGBMH), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

<sup>5</sup>Research Group Genome Organization and Function, DKFZ and BioQuant, 69120 Heidelberg, Germany

<sup>6</sup>UFZ, Helmholtz Centre for Environmental Research Leipzig, Department of Environmental Immunology, 04318 Leipzig, Germany

<sup>7</sup>Division of Epigenomics and Cancer Risk Factors, DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

<sup>8</sup>Department of Neuropathology, University of Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany

<sup>9</sup>Clinical Cooperation Unit Neuropathology, DKFZ, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany

<sup>10</sup>Department of Oncogenomics, AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands

<sup>11</sup>Institute of Human Genetics, Christian-Albrechts-University, Schwanebergweg 24, 24105 Kiel, Germany

<sup>12</sup>Institute of Pathology, Charité-University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany

<sup>13</sup>Division of Neurosurgery and The Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, 555 University Avenue, Toronto M5G 1X8, Canada

<sup>14</sup>Department of Pediatric Oncology, Hematology, and Immunology, Heidelberg University Hospital, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany

<sup>15</sup>Department of Trauma and Orthopaedic Surgery, BG Trauma Centre, 67071 Ludwigshafen, Germany

<sup>16</sup>Max Planck Institute for Molecular Genetics, Ihnestr. 63-73, 14195 Berlin, Germany

<sup>17</sup>Genomics and Proteomics Core Facility, DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

<sup>18</sup>German Cancer Consortium (DKTK), 69120 Heidelberg, Germany

<sup>19</sup>Division of Molecular Genetics, DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

<sup>20</sup>Institute of Pharmacy and Molecular Biotechnology, Bioquant Center, University of Heidelberg, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany

<sup>21</sup>Heidelberg Center for Personalized Oncology, DKFZ-HIPO, DKFZ, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany

\*Correspondence: [r.eils@dkfz-heidelberg.de](mailto:r.eils@dkfz-heidelberg.de)

<http://dx.doi.org/10.1016/j.cell.2013.09.042>

Open access under [CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/) license.

## SUMMARY

Mutation is a fundamental process in tumorigenesis. However, the degree to which the rate of somatic mutation varies across the human genome and the mechanistic basis underlying this variation remain to be fully elucidated. Here, we performed a cross-cancer comparison of 402 whole genomes comprising a diverse set of childhood and adult tumors, including both solid and hematopoietic malignancies. Surprisingly, we found that the inactive X chromosome of many female cancer genomes accumulates on average twice and up to four times as many somatic mutations per megabase,

as compared to the individual autosomes. Whole-genome sequencing of clonally expanded hematopoietic stem/progenitor cells (HSPCs) from healthy individuals and a premalignant myelodysplastic syndrome (MDS) sample revealed no X chromosome hypermethylation. Our data suggest that hypermethylation of the inactive X chromosome is an early and frequent feature of tumorigenesis resulting from DNA replication stress in aberrantly proliferating cells.

## INTRODUCTION

The process of somatic mutation is fundamental to cancer development. A number of causes for these mutations have been

described, including intrinsic mutation processes such as damage from endogenous reactive oxygen species or incomplete fidelity of the DNA replication machinery and extrinsic factors such as environmental and lifestyle exposures. For example, UV light and tobacco exposure are both well-known factors adding to the mutational burden of somatic cells (Stratton et al., 2009).

Human germline mutation rates are not constant across the genome, varying with factors such as base composition and transcription levels (Hodgkinson and Eyre-Walker, 2011; Ellegren et al., 2003). It is also known that the X chromosome typically shows reduced variation compared with the autosomes (Malcom et al., 2003). Only recently, however, have some studies elucidated the existence of variation in genome-wide somatic mutation rates and potential causes thereof. The mutation rate varies within a cancer genome according to underlying genomic features such as GC content, CpG islands, and recombination rate (Greenman et al., 2007). Regions that are actively transcribed have mutation rates at least 25% lower than nontranscribed regions (Chapman et al., 2011) due to mechanisms of transcription-coupled repair. Chromatin organization, specifically the level of heterochromatin-associated histone modification H3K9me3, has been reported to account for more than 40% of mutation-rate variation (Schuster-Böckler and Lehner, 2012). Late-replicating regions also have a higher mutation rate than early-replicating regions in cancer as well as in the germline (Liu et al., 2013; Stamatoyannopoulos et al., 2009).

The inactive X chromosome (Xi) is one of the latest replicating regions of the human genome, being replicated distinctly later in S phase than the autosomes and its active X counterpart (Xa; Hansen et al., 1996; Morishima et al., 1962). In contrast to the autosomes, for which two active copies are present, both male and female cells carry only one active X chromosome. In mammals, dosage compensation between male and female cells is achieved by inactivating one of the two female X chromosomes (Chow and Heard, 2009; Lyon, 1961). This results in transcriptional silencing of most of the ~1,500 genes located on the human X chromosome, although about 3%–15% of genes are known to escape X chromosome inactivation (XCI), depending on cell type (Carrel and Willard, 2005). XCI is initiated very early in embryonic stem cell differentiation and is characterized by a stochastic choice of the X chromosome subjected to inactivation (Barakat and Gribnau, 2012). The chosen inactivated copy (Xi) is then stably maintained through all subsequent cell divisions. The transcription of X-inactive-specific transcript (XIST) RNA, a 17 kb spliced and polyadenylated RNA with no coding capacity, is monoallelically upregulated at the onset of XCI and associates with the future Xi in *cis* (Brown et al., 1992). This XIST coating of the Xi provides the template for a series of histone modifications, including histone-H3 lysine 9 and 27 methylation and histone-H4 deacetylation and macroH2A accumulation, ultimately leading to heterochromatin formation (Plath et al., 2002). After XCI, XIST is expressed continuously and exclusively from the inactive copy of the X chromosome.

In this study, we performed a cross-cancer analysis based on 402 whole-cancer genomes, including our own published and new cancer genome data sets from six different entities (medulloblastoma [Jones et al., 2012; M.K., D.T.W.J., N.J., P.A.N.,

M.D.T., R.E., S.M.P., and P.L., unpublished data], pilocytic astrocytoma [Jones et al., 2013], glioblastoma [S.M.P., M.K., D.T.W.J., P.A.N., M.D.T., R.E., P.L., and A.K., unpublished data], ependymoma [S.C.M., H.W., P.A.N., D.T.W.J., N.J., S.M.P., and M.D.T., unpublished data], B cell lymphoma [Richter et al., 2012; M.S., J.R., M.H., P.L., R.E., and R.S., unpublished data], and prostate carcinoma [Weischenfeldt et al., 2013]), in addition to published mutation call sets of six different cancer types: breast cancer (Nik-Zainal et al., 2012), neuroblastoma (Molenaar et al., 2012), chronic lymphocytic leukemia (CLL, Puente et al., 2011), acute myeloid leukemia (AML, Welch et al., 2012), colorectal carcinoma (Bass et al., 2011), and retinoblastoma (Zhang et al., 2012).


In many female cancer genomes, we unexpectedly found hypermutation of the X chromosome—i.e., a clearly elevated density of mutations compared with the individual autosomes. We show that this hypermutation of the X chromosome is confined to the inactive X chromosome and involves single-nucleotide variants (SNVs) as well as small insertions and deletions (indels), which both show a marked increase in mutations along the X chromosome. Whole-genome sequencing of three independent clonal expansions of healthy hematopoietic stem/progenitor cells and one sample from myelodysplastic syndrome (MDS), which, although clonal, is considered a premalignant condition, revealed no X chromosome hypermutation. Thus, X chromosome hypermutation is a common feature of female cancer genomes occurring across a wide range of tumor types.

## RESULTS

### The X Chromosome Accumulates Significantly More Mutations Than Autosomes in Medulloblastoma Genomes from Female Samples

We analyzed the genome-wide distribution of somatic SNVs in 113 primary medulloblastoma samples collected within the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. The tumors, together with matched normal DNAs, were sequenced to average 30- to 40-fold coverage (Jones et al., 2012; M.K., D.T.W.J., N.J., P.A.N., M.D.T., R.E., S.M.P., and P.L., unpublished data; Table S1 available online). To analyze the distribution of mutations in the genome, the intermutation distance (the distance between a given somatic SNV and the SNV immediately upstream) was plotted for each sample. The mutational patterns revealed by this analysis are outlined below using an exemplary female and male genome (Figures 1A and 1B), which both belong to the same tumor subgroup (Sonic Hedgehog pathway-activated medulloblastoma).

A lower mean intermutation distance on the X chromosome (0.33 Mb) compared with the autosomes (1.2 Mb) was observed in the female sample (Figure 1A), corresponding to a much higher number of mutations on the X chromosome than on any of the individual autosomes. In most cases, the X chromosome harbored a higher number of SNVs than both chromosomes 1 and 2 combined (e.g., MB56 in Figure 1A), even though each of them is much larger in size than the X chromosome. Further, MB56 has a total of 2,887 somatic SNVs in its genome, 469 (16%) of which are located on the X chromosome (Figure 1A). Given the size of the X chromosome, which at ~155 megabases is very



**Figure 1. Distribution of Somatic Mutations in Medulloblastoma Genomes of Female versus Male Samples**

(A) Intermutation distance plot of medulloblastoma MB56 (female). Mutations are ordered on the x axis from the first variant on the short arm of chromosome 1 to the last variant on the long arm of chromosome X. The distance between each somatic SNV and the SNV immediately upstream (the intermutation distance) is plotted on the y axis on a log scale. The chromosomes are separated by thin lines; chromosome X mutations are colored in gray. See also [Figure S1](#).

(B) Intermutation distance plot for medulloblastoma MB61 (male).

(C) To present mutational load per chromosome corrected for the size of the respective chromosome, the mutation rate per megabase was plotted for female MB56. Coloring of bars represents the ratio of the six possible nucleotide changes (C > A, C > G, C > T, T > A, T > C, and T > G) for each chromosome.

(D) Mutational load per chromosome for MB61.


similar in size to chromosome 7, only about 5% of SNVs would be expected to occur on the X chromosome by chance, as is the case for chromosome 7 ( $n = 145$  SNVs, 5.0%). In the male genome, no such difference in mutation rate between the X chromosome and the autosomes was observed ([Figure 1B](#)). Both exemplary tumor genomes are diploid, with no copy number or structural variations except for partial 10q loss in the female sample ([Figure S1](#)). Therefore, copy number changes of the chromosomes do not explain the large difference of SNVs on the X chromosome.

To present mutational load per chromosome corrected for the size of the respective chromosome, the mutation rate per megabase was plotted ([Figures 1C and 1D](#)). Coloring of bars represents the proportions of the six possible nucleotide changes (C > A, C > G, C > T, T > A, T > C, and T > G) for each chromosome. This presentation of the chromosomal distribution of SNVs shows that the X chromosome accumulated 3.6-fold more somatic mutations per megabase compared to the mean of all autosomes in sample MB56 ([Figure 1C](#)). If the number of mutations per megabase on X is at least twice that of the mean

mutation rate of the autosomes, we use the term “X chromosome hypermutation.” The majority of medulloblastoma cancer genomes of female patients (20/25, 80%) showed X chromosome hypermutation ([Figure 2A](#)).

The expected number of SNVs depends on the copy number state of each chromosome. Thus, copy number changes of each chromosome have to be considered as confounding variables when comparing number of somatic SNVs per chromosome. To correct for copy number state of the autosomes, we considered only diploid medulloblastoma genomes with at most six copy number aberrant chromosomes and excluded the respective chromosomes per case; 49/113 cases fulfilled these criteria ([Figure 2A](#)). For all remaining cases, we can only infer X hypermutation to be present or not—we cannot accurately estimate the strength of X hypermutation.

In general, male medulloblastoma genomes do not show X chromosome hypermutation ([Figures 1D and 2A](#)). Male genomes have only one copy of X in the germline; therefore, the amount of mutations on the X chromosome needs to be



**Figure 2. The X Chromosome Accumulates Significantly More Mutations Than Autosomes in Cancer Genomes of Female Samples**

(A) X chromosome mutation ratio of 49 medulloblastoma genomes. The X chromosome mutation ratio (values on y axis) is calculated as mutation rate of X chromosome divided by the mean mutation rate of all autosomes. A ratio of  $\geq 2$  indicates X chromosome hypermutation.

(B) Age at diagnosis of the 49 medulloblastoma patients.

(C) XIST expression status of the 49 medulloblastoma genomes.

(D–G) (D) Distribution of the X chromosome mutation ratio for males (raw values and corrected for single X copy number state) and females (with both X copies) in medulloblastoma, (E) in neuroblastoma, (F) in pilocytic astrocytoma, and (G) in B cell lymphoma (n = 29, without sample 4120193). p values from t test.

See also Figure S2.

**Table 1. Overview of 402 Cancer Genomes Analyzed in This Study**

Cancer Type	Cases Total	Cases Female	Cases Male	X Hyper-mutation Female	X Hyper-mutation Male	Remark	Reference
Acute myeloid leukemia	24	11	13	1	0	1 female with <200 SNVs	<a href="#">Welch et al. (2012)</a>
B cell lymphoma	30	9	21	3	0	2 females with chrX loss	<a href="#">Richter et al. (2012)</a> ; M.S., J.R., M.H., P.L., R.E., and R.S., unpublished data
Breast cancer	21	21	NA	2	NA	15 cases have partial or complete chrX loss	<a href="#">Nik-Zainal et al. (2012)</a>
Chronic lymphocytic leukemia	4	2	2	0	0		<a href="#">Puente et al. (2011)</a>
Colorectal adenocarcinoma	9	6	3	0	0		<a href="#">Bass et al. (2011)</a>
Ependymoma	5	1	4	1	0		S.C.M., H.W., P.A.N., D.T.W.J., N.J., S.M.P., and M.D.T., unpublished data
Glioblastoma	1	1	NA	1	NA		S.M.P., M.K., D.T.W.J., P.A.N., M.D.T., R.E., P.L., and A.K., unpublished data
Medulloblastoma	113	48	65	29	0	14 females with chrX loss; 1 female with <200 SNVs	<a href="#">Jones et al. (2012)</a> ; M.K., D.T.W.J., N.J., P.A.N., M.D.T., R.E., S.M.P., and P.L., unpublished data; P.A.N., M.K., D.T.W.J., N.J., M.D.T., R.E., S.M.P., P.L., unpublished data
Neuroblastoma	84	36	48	8	0	6 females with chrX loss; 8 females with <200 SNVs	<a href="#">Molenaar et al. (2012)</a>
Pilocytic astrocytoma	96	54	42	10	0	36 females with <200 SNVs	<a href="#">Jones et al. (2013)</a>
Prostate carcinoma	11	NA	11	NA	0		<a href="#">Weischenfeldt et al. (2013)</a>
Retinoblastoma	4	2	2	1	0	1 female with <200 SNVs	<a href="#">Zhang et al. (2012)</a>
Summary	402	191	211	56	0	additional 27 females with increased X mutation rate; see <a href="#">Table S1</a>	

See also [Table S1](#).

doubled in order to correct for copy number status. Even after correcting the mutation rate of the X chromosome in males, the difference between female versus male X chromosome mutation rate is highly significant in medulloblastoma ( $p = 8 \times 10^{-11}$ , t test) and in three other tumor types ([Figures 2D–2G](#)). We note that, after this correction, a few male samples enter the range of our definition of X chromosome hypermutation ([Figure 2A](#)). This might be explained by the fact that hemizygous mutations on the single X chromosome in males can be more readily called by mutation calling algorithms than heterozygous mutations in female samples, which will typically be supported by fewer reads. However, the ratio of X chromosome versus autosome mutation rate in males and in females with X chromosome loss ranges from about 0.5 to 1, or 1- to 2-fold after correcting for the single copy of X, whereas we observe a range of ~2- to 4-fold higher mutation rates when both Xa and Xi are present. This suggests that Xi accumulates at least twice as many mutations as Xa.

Note that the variation in strength of X chromosome hypermutation observed in the medulloblastoma female samples ([Figure 2A](#)) does not correlate with age at diagnosis ([Figure 2B](#)), which is in contrast to the finding that the overall number of somatic mutations in medulloblastoma strongly correlates with age ([Jones et al., 2012](#)).

### X Hypermutation Is Confined to the Inactive X Chromosome

Most, but not all, medulloblastoma genomes from female patients display X chromosome hypermutation ([Tables 1 and S1](#) and [Figure 2A](#)). We therefore further examined those cases not displaying this phenomenon. First, medulloblastoma genomes from females with loss of an X chromosome in the tumor (resulting in only one copy of the X chromosome) do not show X chromosome hypermutation ([Figure 2A](#); for example, MB18). However, it is not the X copy number state in itself that determines X hypermutation. Tetraploid female sample MB6 has two copies of the X chromosome but has loss of heterozygosity and no *XIST* expression ([Figure S2](#)). Indeed, all medulloblastoma genomes from female samples that lost one copy of the X chromosome also show no *XIST* expression, indicating that Xa is kept and Xi is lost ([Figure 2C](#)). We did not observe X chromosome hypermutation in MB6 (with two copies of Xa; [Figure S2B](#)) and consistently found no X hypermutation in cases that lost Xi, regardless of the absolute copy number state of X. Further, X hypermutation is not present in male tetraploid genomes with more than one copy of the X chromosome. These analyses indicate that the copy number state of the X chromosome does not impact X hypermutation but rather indicates that it depends on the presence of Xi. Remarkably, a medulloblastoma

from a male patient (MB139) with Klinefelter syndrome (47, XXY genome) also shows a trend toward X chromosome hypermutation (Figure 2A). The matching RNA data confirm XIST expression and therefore presence of Xi (Figure 2C).

To further study the confinement of hypermutation to Xi, we performed two different approaches. First, for two samples (MB101 and lymphoma 4120193) with high mutational load and imbalanced copy number states of Xi versus Xa, we assigned individual SNVs to the active/inactive X chromosome by in silico haplotype phasing of mutations. Second, we performed chromatin immunoprecipitation sequencing (ChIP-seq) for histone marks H3K36me3 and histone variant macroH2A1 in order to haplotype the X chromosome of two additional samples (MB59 and GBM103).

For haplotype phasing, we attempted to phase mutations that are sufficiently close together to be spanned by single read pairs. The first 52 megabases of chromosome arm Xp in female sample MB101 are present at three copies in the tumor. RNA sequencing (RNA-seq)-based allele frequencies of germline variants clearly identify Xi being present with two copies and Xa with a single copy. In total, 222 somatic SNVs were called in this region. Many somatic mutations were sufficiently close to heterozygous germline SNPs that individual sequence read pairs spanned both, thus allowing the mutation to be phased with the SNP. Here, a germline SNP with an allele frequency of about 1/3 indicates that this mutation is on Xa, whereas an allele frequency of 2/3 indicates that this mutation is located on Xi. In total, 58 somatic SNVs were haplotyped by this approach, of which 46 unambiguously mapped to Xi and 12 to Xa ( $p < 0.0001$ , permutation test). Even when doubling the amount of Xa mutations in order to correct for the single copy state of Xa in MB101, the difference is still significant (24 Xa versus 46 Xi mutations;  $p = 0.006$ ).

The same haplotyping approach was applied to X chromosome hypermutated lymphoma sample 4120193 (female), for which most of the Xq arm is present at three copies in the tumor (Figure 3). Here, RNA-seq-based allele frequencies of germline variants indicate that Xi has two copies and Xa has a single copy. The sample has a high genome-wide mutational load with 3,756 somatic SNVs on the X chromosome alone. Of those SNVs, 444 were haplotyped, of which 389/444 SNVs unambiguously mapped to Xi and 55/444 mapped to Xa ( $p < 0.0001$ , permutation test). Doubling the amount of Xa mutations ( $n = 110$ ) in order to correct for the single copy state of Xa still results in 3.5× more mutations on Xi. Interestingly, this sample also shows focal regions of higher intermutation distance on the X chromosome (Figure 3A), corresponding to lower mutation rates. These regions with fewer mutations harbor genes escaping X inactivation, as well as the pseudoautosomal regions PAR1 and PAR2 (Figure 3B). In addition, we compared medulloblastoma female samples with X hypermutation ( $n = 10$ ) with male samples ( $n = 10$ ) of the same tumor subtype and ploidy and found that regions escaping X chromosome inactivation have a mean mutation rate of 1/Mb in both male and female samples. Thus, regions escaping X chromosome inactivation are not X hypermutated, further supporting our finding that X hypermutation is confined to heterochromatic regions of the inactive X chromosome.

To haplotype the X chromosome of two additional samples (MB59 and GBM103), we performed ChIP-seq for histone marks H3K36me3 and macroH2A1. Histone variant macroH2A1 is known to show an ~1.5-fold uniform enrichment along the inactive X chromosome (Mietton et al., 2009). In contrast, H3K36me3 is enriched in actively transcribed regions and therefore on Xa. Thus, by sequencing both histone marks to sufficiently high depth to infer allele frequencies of mutations, a mutation on Xi should have a high allele frequency in the macroH2A1 reads and a low allele frequency in H3K36me3, which we clearly observed for the germline mutations (data not shown). Integrating matching RNA-seq data with mutations showing particularly high/low macroH2A1/H3K36me3 allele frequencies (Extended Experimental Procedures), 31 SNVs were haplotyped in glioblastoma GBM103, with only 3 SNVs locating to Xa ( $p < 0.0001$ , permutation test). In medulloblastoma MB59, eight SNVs were haplotyped, of which only two mapped to Xa.


Most X hypermutated samples have no RNA-seq read support at mutated positions because these mutations localize mainly to intergenic regions. However, a pool of 16 medulloblastoma samples had in total 22 somatic SNVs sufficiently covered in the patient-matched RNA sequencing data (excluding genes that escape X inactivation). Of these 22 mutations, 21/22 mutations were not present in the RNA despite sufficient RNA coverage at the mutated position and are therefore likely to be present on the inactive X ( $p < 0.0001$ , permutation test).

X chromosome hypermutation was observed in all medulloblastoma samples of female patients in which the inactive X chromosome was present, and haplotyping of four individual samples clearly indicates that X hypermutation is confined to the inactive X chromosome.

### X Chromosome Hypermutation Is a Feature of Many Different Cancer Types

To assess whether X chromosome hypermutation is a general feature of multiple tumor types, we analyzed the somatic mutation rate of the X chromosome in an additional ~300 whole-cancer genomes, including our own published and unpublished data from five different cancer entities (pilocytic astrocytoma, glioblastoma, ependymoma, B cell lymphoma, and prostate carcinoma) complemented by published mutation call sets of six different cancer types: breast cancer (Nik-Zainal et al., 2012), neuroblastoma (Molenaar et al., 2012), chronic lymphocytic leukemia (Puente et al., 2011), acute myeloid leukemia (Welch et al., 2012), colorectal carcinoma (Bass et al., 2011), and retinoblastoma (Zhang et al., 2012). We observed X chromosome hypermutation in a significant fraction of cancer genomes from female samples (56/191, 29%) comprising nine different cancer entities across a diverse set of childhood tumors as well as adult solid and hematopoietic malignancies (Tables 1 and S1 and Figure 4).

In contrast to medulloblastoma, not every female cancer genome containing Xi in the other cancer types displays X hypermutation, as far as information about Xi status was available. In the two female cases of CLL, no X hypermutation was detected. This was also the case for the six female samples of colorectal carcinoma by the strict definition given above, but in two genomes of female samples, the X chromosome showed the highest mutation rate of all chromosomes. If we include all



**Figure 3. Fewer Mutations in Regions Escaping X Chromosome Inactivation**

(A) Genome-wide intermutation distance plot of lymphoma 4120193 (DLBCL subtype, female).

(B) X chromosome-wide intermutation distance plot of somatic mutations along the X chromosome coordinates. Genes that escape X inactivation and are expressed in this sample as determined by RNA-seq data show fewer mutations (marked in gray).


(C) X chromosome copy number plot of lymphoma 4120193; 81 Mbs of the Xq arm are present at three copies in the tumor.

The asterisk in all three panels marks the same mutation (the first mutation after the centromere).

female cases of the different cancer types with an increased mutation rate, but not X chromosome hypermutation by our strict definition, then 83/191 (43%) females are affected. Some of the cancer genomes had extremely low amounts of somatic mutations (<200 SNVs), specifically in the pediatric tumors pilocytic astrocytoma and neuroblastoma (Table S1), which

makes detection of X chromosome hypermutation impossible for a single sample.

Interestingly, a breast cancer genome with about 10,000 mutations showed clear X chromosome hypermutation, as did a retinoblastoma genome of a 21-month-old patient with only 258 mutations (Figures 4A and 4B). Thus, the occurrence of



**Figure 4. X Chromosome Hypermutation Is a Feature of Many Different Cancer Types**

Mutations per chromosome plot for exemplary genomes from female samples of (A) breast cancer, (B) retinoblastoma, (C) B cell lymphoma, (D) neuroblastoma, (E) glioblastoma, and (F) AML. See also [Figure S3](#).

X chromosome hypermutation cannot simply be explained by the total number of somatic mutations or by age at diagnosis. Some cancer genomes from females with a very high number of somatic mutations, like some of the breast cancer ([Nik-Zainal](#)

[et al., 2012](#)) and colorectal adenocarcinoma genomes ([Bass et al., 2011](#)), do not show X hypermutation. It may be that, in some tumors, local hypermutation due to processes such as *kataegis* ([Nik-Zainal et al., 2012](#)) might mask the general



accumulation of mutations on Xi. We also observed X chromosome hypermutation in a recurrence of medulloblastoma MB34 (Jones et al., 2012), with the same degree of hypermutation as in the primary tumor despite a higher number of mutations genome wide (data not shown).

Our analyses thus indicate that X chromosome hypermutation is present in many diverse types of cancer genomes from female patients but to varying degrees within each cancer type in terms of strength of X hypermutation and number of affected samples.

### Characteristics of X Chromosome Hypermutation in Medulloblastoma

Next, we examined whether X chromosome hypermutation is an early or late event in tumorigenesis. Because tetraploidy is known to be a frequent early event in medulloblastoma tumorigenesis (Jones et al., 2012), we assessed whether X hypermutation is already present before tetraploidy occurs. For this analysis, we considered only mutations with a clear ~50% allele frequency because allele frequencies of ~25% indicate a mutation on only one of the four alleles present after genome duplication. In the tetraploid genome of MB101 (Figure 5A), only 7% of genome-wide mutations are ~50% heterozygous—i.e., present before tetraploidy occurred—indicating that most mutations arise after tetraploidy. However, X hypermutation is already clearly observable in the fraction of SNVs present before genome duplication (Figure 5B), demonstrating that this phenomenon develops even earlier during tumor evolution.

Interestingly, X chromosome hypermutation is not confined to SNVs but is also observed for somatic indels in those genomes that display X hypermutation based on SNVs (Figures 5C and 5D).

X chromosome hypermutation is also clearly a somatic phenomenon, as notably fewer germline polymorphisms occur on the X chromosome compared to the autosomes in our medulloblastoma samples (Figure 5E). Indeed, it is a well-known phenomenon that germline variation is found to be lowest on the X chromosome, with an ~30% lower rate than for the autosomes (Hodgkinson and Eyre-Walker, 2011).

The distribution of mutations between exons, introns, and intergenic DNA is not different on the hypermutated X chromosome compared to the autosomes (Figure 5F). Lack of transcription-coupled repair on the largely transcriptionally silent Xi is unlikely a cause for X hypermutation given the predominantly intergenic location. Further, X chromosome hypermutation cannot be linked to hypermethylation of Xi at gene promoters, leading to spontaneous deamination of cytosine because no increase in the fraction of C > T mutations was found (Figures 1C and 4).

### Similar Mutation Spectrum on Autosomes and the Hypermutated X

Within an individual cancer genome, there is no substantial variation between the autosomes and X chromosome in the relative contributions of each of the six classes of base substitution (C > A, C > G, C > T, T > A, T > C, and T > G) (Figure 4). Thus, the hypermutated X chromosome has the same mutation spectrum as the autosomes. This holds true even in those cases of lymphoma or neuroblastoma that have a very unique mutation spectrum (Figures 4C and 4D). To provide further insight into the

underlying mutational processes, we incorporated the sequence context in which mutations occurred by considering the bases immediately 5' and 3' to each mutated base, giving 96 possible trinucleotide contexts for a mutation. The resulting heatmap reveals that the mutational signatures on the autosomes and the X chromosome are very similar (Figure S3).

Further, principal component analysis (PCA) shows that the mutation spectrum of the autosomes and the hypermutated X chromosome of individual samples within one tumor type cluster closer together than the hypermutated X chromosomes of different tumors (Figure S4A). In addition, the distribution of mutations along the hypermutated X chromosome is very similar to the distribution observed on X in males of the same tumor type (e.g., for B cell lymphoma  $r^2 = 0.64$ ,  $p < 2 \times 10^{-16}$ , Pearson's product-moment correlation; Figures S4B and S4C).

We conclude that Xi is hypermutated during tumorigenesis by the same processes that cause mutations on the autosomes and Xa as opposed to Xi-specific mutational processes.

### Autosomal Regions as Highly Mutated as the X Chromosome Are Late Replicating


Late-replication timing is known to increase the mutation rate (Liu et al., 2013). Because regions subject to X inactivation are known to be late replicating (Hansen et al., 1996; Morishima et al., 1962), we analyzed whether the autosomes have late-replicating regions as strongly mutated as the hypermutated X chromosome. We used the RepliSeq replication timing data (<http://genome.ucsc.edu/ENCODE>) for 10 different cell lines and focused on genomic regions that maintain similar replication timing between these different cell types. Similar to the definition of X chromosome hypermutation, we defined an autosomal region to be hypermutated if this region had at least twice the number of mutations compared to the mean mutation rate of the autosomes. At the 1 Mb scale, the highest mutated regions are almost all late replicating, with very few exceptions (Figure 6). These conclusions were upheld when using alternative genomic window sizes of 100 kb or 5 Mb (Figure S5). Not every late replicating autosomal region, however, displayed hypermutation.

For B cell lymphoma (Figure 6B), we used only the RepliSeq data for lymphoblastoid cell lines ( $n = 5$ ) to match the tumor cell of origin. The immunoglobulin loci *IGH*, *IGK*, and *IGL*, which are known to undergo AID-mediated somatic hypermutation in germinal center B cells, were excluded (and showed early replication timing). However, additional regions affected by AID-mediated somatic hypermutation in germinal center B-cell-derived lymphomas, such as the *MYC* gene region in Burkitt lymphomas and the *BCL2* gene region in follicular lymphomas, were not excluded and appear as early-replicating, hypermutated regions in this analysis (Figure 6B).

Notably, very few regions on the autosomes are mutated at a high frequency as the hypermutated X chromosome. Thus, autosomes are also affected by hypermutation in late-replicating regions but to a much lesser extent than Xi.

### Whole-Genome Sequencing of Nonmalignant Somatic Cells Reveals No X Chromosome Hypermutation

Because X chromosome hypermutation is an early event in tumorigenesis of medulloblastoma and is observed across a



**Figure 5. Characteristics of X Chromosome Hypermutation in Medulloblastoma**

(A and B) Mutational load per chromosome for female tetraploid medulloblastoma MB101 (A) for all somatic SNVs and (B) only for somatic SNVs with a clear ~50% allele frequency, demonstrating X hypermutation to occur before tetraploidy.

(C) Intermutation distance plot for genome-wide somatic indels of MB101.


(D) X hypermutation is observed for indels (y axis) in those genomes that display X hypermutation based on SNVs (x axis). Values on axes calculated as mutation rate of X chromosome divided by the mean mutation rate of all autosomes.

(E) Mutational load per chromosome for MB101 using all germline single nucleotide substitutions shows that the X chromosome has less germline substitutions than the autosomes.


(F) Distribution of somatic SNVs per chromosome into different genomic regions.

See also [Figure S4](#).

**A** Repli-Seq replication timing versus somatic SNVs on chr1–22 in medulloblastoma (n=113)  
1Mb window size



**B** Repli-Seq replication timing versus somatic SNVs on chr1–22 in B-cell lymphoma (n=29)  
1Mb window size



variety of very diverse cancer types, we sought to elucidate whether X hypermutation is a general feature of normal somatic cells from females, arising independent of tumorigenesis. We therefore performed whole-genome sequencing of two clonally expanded, single CD34+ CD38– hematopoietic stem/progenitor cells (HSPCs) derived from bone marrow mononuclear cells of a healthy 73-year-old female. The two genomes harbored about 1,300 and 1,500 somatic point mutations, respectively, which we were able to call as “somatic” by comparing against whole-genome sequence data derived from the matching bulk bone marrow cells. Despite the relatively high number of somatic SNVs in these two healthy cells, we did not observe X chromosome hypermutation (Figures 7A and 7B). In addition, one HSPC clone derived from peripheral blood of a healthy 39-year old female was

### Figure 6. Autosomal Regions as Highly Mutated as the X Chromosome Are Late Replicating

(A) RepliSeq replication timing data (y axis) versus somatic mutations per 1 Mb window (x axis) of the merged mutation set of medulloblastoma genomes (n = 113) including only the autosomes. An autosomal region in this analysis is defined as hypermutated if  $\geq 2$ -fold mutation rate compared to the mean mutation rate of the autosomes (here,  $>118$  SNVs per 1 Mb). The RepliSeq data are a wavelet-smoothed, weighted average signal where high and low values indicate early and late replication during the S phase, respectively (y axis).

(B) Replication timing correlation for B cell lymphoma (n = 29, without sample 4120193). Autosomal regions with  $>125$  SNVs per 1 Mb are defined here as hypermutated.

See also Figure S5 for alternative genomic window sizes of 100 Kb and 5 Mb.

sequenced and compared against the matching peripheral blood, but X hypermutation was not observed in the 442 somatic mutations (Figure 7C).

Next, we studied one sample derived from secondary MDS arising after treatment for medulloblastoma in an 11-year-old female Li-Fraumeni syndrome case (LFS-MB1). Although clonal, MDS is considered a premalignant condition with a propensity to progress to AML when additional genetic abnormalities are acquired. We did not observe X hypermutation in this MDS genome, despite a total of 825 somatic point mutations (Figure 7D). In contrast, the medulloblastoma genome of this Li-Fraumeni syndrome case is one of the strongest X hypermutated samples in our data set (Figure 7E).


Thus, from the four samples studied, we did not find evidence for X chromo-

some hypermutation in noncancerous, clonally expanded cell populations.

## DISCUSSION

### Hypermutation of the Inactive X Chromosome in Cancer Genomes

Our analysis of more than 400 cancer genomes from 12 different cancer entities revealed the finding that the X chromosome of female patients frequently accumulates twice as many somatic mutations per megabase compared to the autosomes, whereas some tumors even accumulate up to four times more mutations on the X chromosome. We provide strong evidence that this X chromosome hypermutation is confined to the inactive X chromosome (Xi). Further, X hypermutation has no similarities with



**Figure 7. Whole-Genome Sequencing of Nonmalignant Somatic Cells Reveals No X Chromosome Hypermutation**

Mutational load per chromosome plot for genomes from female samples of (A) HSPC clone B6 and (B) HSPC clone G2 of a healthy 73-year-old female, (C) HSPC clone of a 39-year-old healthy female, (D) MDS of Li-Fraumeni syndrome case LFS-MB1, and (E) medulloblastoma of Li-Fraumeni syndrome case LFS-MB1.

the focal somatic hypermutation present in normal immune cells or with the recently described *kataegis* phenomenon observed in some tumors, which is thought to be linked to APOBEC family cytidine deaminase activity (Nik-Zainal et al., 2012).

We used data from different sequencing technologies (Illumina and Complete Genomics) sequenced at different centers and analyzed with different alignment algorithms and mutation calling pipelines. In addition, all genomic somatic mutations from the University of Washington (AML and retinoblastoma; Welch et al., 2012; Zhang et al., 2012) were validated by orthogonal sequencing technologies, which preclude X chromosome hypermutation being an artifact of next-generation sequencing technology and/or analysis methodology.

We sequenced four nonmalignant genomes (three female samples of HSPCs and one female MDS case) and found no X hypermutation, despite a sufficiently high number of somatic mutations, which would have allowed for the identification of X hypermutation if it were present. Although we cannot conclusively exclude, based on the analysis of these four genomes, that the higher accumulation of mutations on Xi is due to random background mutations in healthy somatic cells from females, we hypothesize that X chromosome hypermutation is a cancer-specific feature.

We propose a model in which Xi accumulates somatic mutations during tumorigenesis not by any specific process acting exclusively on Xi but by a higher burden of the same processes mutating the autosomes, thereby resulting in the same mutational spectrum as observed on the autosomes. If Xi hypermutation would be attributed solely to the unique heterochromatin structure of Xi, one would expect Xi hypermutation to occur also in normal cells and cancer genomes from female samples in general, which we did not observe. The mutations on Xi seem not to be detected and/or repaired as efficiently as on the autosomes and Xa. Alternatively, it has been reported that a shortage of nucleotides during late S phase could lead to erroneous incorporation of nucleotides, thus suggesting rather elevated mutagenesis than impaired repair causing X hypermutation (Burrell et al., 2013). Xi is known to be extremely late replicating in S phase (Hansen et al., 1996; Morishima et al., 1962), and other late-replicating regions on the autosomes also displayed markedly higher mutation rates. Thus, Xi might not be properly repaired in aberrantly proliferating cells as a result of a shorter and/or compromised late S phase caused by DNA replication stress.

This hypothesis is supported by our analysis of retinoblastoma, an aggressive childhood cancer initiated by the biallelic loss of *RB1*. Tumors progress very quickly following *RB1* inactivation and thereby experience DNA replication stress (Tort et al., 2006). The retinoblastoma genome of a 21-month-old patient with only 258 mutations genome wide (Zhang et al., 2012) already shows strong X chromosome hypermutation, with a three times higher mutation rate on chromosome X than on the autosomes (Figure 4B).

A second rapidly growing, malignant childhood tumor, medulloblastoma (Northcott et al., 2012), is also one of the entities most commonly displaying X chromosome hypermutation. All medulloblastoma genomes from females with two different copies of the X chromosome (i.e., a maternal and a paternal

copy) show X hypermutation or an increased rate of X chromosomal mutations. Further, X hypermutation is already present before tetraploidy, a known early event in this tumor (Jones et al., 2012). This would be in keeping with our hypothesis that replication stress may be one of the prerequisites for X chromosome hypermutation because replication stress is one of the earliest events in tumorigenesis (Bester et al., 2011) and is also known to cause tetraploidy.

Remarkably, the medulloblastoma genome of female Li-Fraumeni syndrome case LFS-MB1 is one of the strongest X hypermutated samples, although the patient's secondary MDS genome shows no X hypermutation (Figure 7D and 7E), supporting our suggestion that X hypermutation is a cancer-specific feature.

Given the data presented here, we hypothesize that hypermutation of Xi is one of the earliest events in tumorigenesis occurring in response to replication stress in cancer cells. Future investigation into the detailed mechanistic basis and extent of hypermutation on the inactive X chromosome may therefore provide novel insights into how tumor cells, and in particular the DNA repair machinery, respond to early oncogenic stresses. Our study makes an important contribution toward ongoing efforts to solve the fundamental question of where and how cancer genomes acquire mutations.

## EXPERIMENTAL PROCEDURES

### Sequence Variant Discovery and Analysis

For our own data sets (medulloblastoma, astrocytoma, B cell lymphoma, ependymoma, glioblastoma, and prostate carcinoma), Illumina sequence data were aligned to the hg19 human reference genome assembly using BWA (Li and Durbin, 2009); duplicate and nonuniquely mapping reads were excluded. We subsequently detected SNVs and InDels with complementary computational approaches (see Extended Experimental Procedures). Somatic genome-wide single-nucleotide variants of published cancer data sets from other institutes were obtained from the supplemental data files of the respective publications; no additional filtering of these mutation call sets was performed.

### Clonal Expansion of Single Healthy Somatic Cells

Bone marrow mononuclear cells from a healthy 73-year-old female were thawed and labeled with Alexa-Fluor 488-conjugated anti-CD34 (581, Biolegend), Alexa-Fluor 700-conjugated anti-CD38 (HIT2, eBioscience), a cocktail of APC-conjugated lineage antibodies consisting of anti-CD4 (RPA-T4), anti-CD8 (RPA-T8), anti-CD11b (ICRF44), anti-CD20 (2H7), anti-CD56 (B159, all BD Biosciences), anti-CD14 (61D3), anti-CD19 (HIB19), and anti-CD235a (HIR2, all eBioscience), and 1  $\mu$ g/ml propidium iodide (Sigma). Using a BD FACSAria cell sorter, single Lin<sup>-</sup>CD34<sup>+</sup>CD38<sup>-</sup>PI<sup>-</sup> cells were individually sorted into low-adhesion 96-well tissue culture plates (Corning) containing 100  $\mu$ l of StemSpan Serum-Free Expansion Medium (Stemcell technologies) supplemented with 100 ng/ml of human SCF and FLT-3L, 50 ng/ml of human TPO, 20 ng/ml of human IL-3, IL-6, and G-CSF (all cytokines from Peprotech), and 50 U/ml of penicillin and 50  $\mu$ g/ml of streptomycin (Sigma). Cells were incubated at 37°C in a humidified atmosphere with 5% CO<sub>2</sub> in air. After 5 days in culture, another 100  $\mu$ l of cytokine-containing medium were added. 13 days after seeding, clones B6 and G2 had expanded to  $\sim 10^5$  cells and were selected for whole-genome sequencing (2  $\times$  101 bp, paired-end, Illumina HiSeq2500) after tagmentation-based library preparation (see Extended Experimental Procedures) for clone B6 and standard library preparation for clone G2. For germline-control,  $\sim 10^6$  unsorted bone marrow mononuclear cells from the same donor were used for sequencing. An average of 30-fold sequence coverage for each the clones and the matching control was obtained.

A progenitor cell clone was raised from a peripheral blood sample of a 39-year-old healthy female. Frozen peripheral blood mononuclear cells (PBMCs) were isolated from 2 ml heparinized peripheral blood via Ficoll Paque density centrifugation. A methylcellulose assay was performed as described earlier (Weisse et al., 2012). In brief, nonadherent mononuclear cells were incubated in the presence of the recombinant human cytokines IL-3, IL-5, and GM-CSF (R&D systems) over 14 days to induce colony formation. Colonies were detected under an inverted light microscope and were plucked by a pipette when colonies had ~10,000 cells/CFU. Each colony was washed three times in PBS and finally frozen as a cell pellet in  $-80^{\circ}\text{C}$ . Genomic DNA was isolated using the QIAamp DNA micro kit according to the instructions of the manufacturer (QIAGEN, Hilden). Whole-genome sequencing ( $2 \times 101$  bp, paired-end, Illumina HiSeq2500) was performed for colony 4 after tagmentation-based library preparation and resulted in 15-fold sequence coverage for each the colony and the matching whole blood.

#### ACCESSION NUMBERS

Next-generation sequencing data have been deposited at the European Genome-phenome Archive (EGA, <https://www.ebi.ac.uk/ega/>) hosted by the EBI under accession numbers EGAS00001000394 and EGAS00001000565.

#### SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures, five figures, and one table and can be found with this article online at <http://dx.doi.org/10.1016/j.cell.2013.09.042>.

#### ACKNOWLEDGMENTS

We would like to acknowledge the members of the PedBrain Tumor and MMML-Seq Project contributing to the ICGC. For technical support and expertise, we thank the DKFZ Genomics and Proteomics Core Facility, specifically Sabine Schmidt and Sasithorn Chotewutmontri. We acknowledge assistance provided by Hans-Jörg Warnatz for RNA sequencing and analysis at the Max Planck Institute for Molecular Genetics. We especially express our gratitude to Edith Heard for very helpful comments on our manuscript. This work was principally supported by the PedBrain Tumor Project and the MMML-Seq Project contributing to the ICGC, funded by German Cancer Aid (109252) and by the German Federal Ministry of Education and Research (BMBF, grants 01KU1201A, MedSys 0315416C and 01KU1002A to 01KU1002J). Additional support came from the German Cancer Research Center Heidelberg Center for Personalized Oncology (DKFZ-HIPO), the Max Planck Society, Genome Canada, and the Canadian Institute for Health Research (CIHR) with cofunding from Genome BC, Genome Quebec, CIHR-ICR (Institute for Cancer Research), and the Dietmar Hopp Foundation.

Received: April 27, 2013

Revised: August 2, 2013

Accepted: September 20, 2013

Published: October 17, 2013

#### REFERENCES

Barakat, T.S., and Gribnau, J. (2012). X chromosome inactivation in the cycle of life. *Development* 139, 2085–2089.

Bass, A.J., Lawrence, M.S., Brace, L.E., Ramos, A.H., Drier, Y., Cibulskis, K., Sougnez, C., Voet, D., Saksena, G., Sivachenko, A., et al. (2011). Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. *Nat. Genet.* 43, 964–968.

Bester, A.C., Roniger, M., Oren, Y.S., Im, M.M., Sami, D., Chaoat, M., Bension, A., Zamir, G., Shewach, D.S., and Kerem, B. (2011). Nucleotide deficiency promotes genomic instability in early stages of cancer development. *Cell* 145, 435–446.

Brown, C.J., Hendrich, B.D., Rupert, J.L., Lafrenière, R.G., Xing, Y., Lawrence, J., and Willard, H.F. (1992). The human XIST gene: analysis of a 17 kb inactive

X-specific RNA that contains conserved repeats and is highly localized within the nucleus. *Cell* 71, 527–542.

Burrell, R.A., McClelland, S.E., Endesfelder, D., Groth, P., Weller, M.-C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S.M., Gronroos, E., et al. (2013). Replication stress links structural and numerical cancer chromosomal instability. *Nature* 494, 492–496.

Carrel, L., and Willard, H.F. (2005). X-inactivation profile reveals extensive variability in X-linked gene expression in females. *Nature* 434, 400–404.

Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibulskis, K., Sougnez, C., Schinzel, A.C., Harview, C.L., Brunet, J.-P., Ahmann, G.J., Adli, M., et al. (2011). Initial genome sequencing and analysis of multiple myeloma. *Nature* 471, 467–472.

Chow, J., and Heard, E. (2009). X inactivation and the complexities of silencing a sex chromosome. *Curr. Opin. Cell Biol.* 21, 359–366.

Ellegren, H., Smith, N.G.C., and Webster, M.T. (2003). Mutation rate variation in the mammalian genome. *Curr. Opin. Genet. Dev.* 13, 562–568.

Greenman, C., Stephens, P., Smith, R., Dalgleish, G.L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007). Patterns of somatic mutation in human cancer genomes. *Nature* 446, 153–158.

Hansen, R.S., Canfield, T.K., Fjeld, A.D., and Gartler, S.M. (1996). Role of late replication timing in the silencing of X-linked genes. *Hum. Mol. Genet.* 5, 1345–1353.

Hodgkinson, A., and Eyre-Walker, A. (2011). Variation in the mutation rate across mammalian genomes. *Nat. Rev. Genet.* 12, 756–766.

Jones, D.T.W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T.J., Hovestadt, V., Stütz, A.M., et al. (2012). Dissecting the genomic complexity underlying medulloblastoma. *Nature* 488, 100–105.

Jones, D.T.W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S.R., Ryzhova, M., Quang, D.A.K., et al.; International Cancer Genome Consortium PedBrain Tumor Project. (2013). Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nat. Genet.* 45, 927–932.

Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25, 1754–1760.

Liu, L., De, S., and Michor, F. (2013). DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. *Nat. Commun.* 4, 1502.

Lyon, M.F. (1961). Gene action in the X-chromosome of the mouse (*Mus musculus* L.). *Nature* 190, 372–373.

Malcom, C.M., Wyckoff, G.J., and Lahn, B.T. (2003). Genic mutation rates in mammals: local similarity, chromosomal heterogeneity, and X-versus-autosome disparity. *Mol. Biol. Evol.* 20, 1633–1641.

Mietton, F., Sengupta, A.K., Molla, A., Picchi, G., Barral, S., Heliot, L., Grange, T., Wutz, A., and Dimitrov, S. (2009). Weak but uniform enrichment of the histone variant macroH2A1 along the inactive X chromosome. *Mol. Cell. Biol.* 29, 150–156.

Molenaar, J.J., Koster, J., Zwijnenburg, D.A., van Sluis, P., Valentijn, L.J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B.A., van Arkel, J., et al. (2012). Sequencing of neuroblastoma identifies chromothripsis and defects in neurogenesis genes. *Nature* 483, 589–593.

Morishima, A., Grumbach, M.M., and Taylor, J.H. (1962). Asynchronous duplication of human chromosomes and the origin of sex chromatin. *Proc. Natl. Acad. Sci. USA* 48, 756–763.

Nik-Zainal, S., Alexandrov, L.B., Wedge, D.C., Van Loo, P., Greenman, C.D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L.A., et al.; Breast Cancer Working Group of the International Cancer Genome Consortium. (2012). Mutational processes molding the genomes of 21 breast cancers. *Cell* 149, 979–993.

Northcott, P.A., Jones, D.T.W., Kool, M., Robinson, G.W., Gilbertson, R.J., Cho, Y.-J., Pomeroy, S.L., Korshunov, A., Lichter, P., Taylor, M.D., and Pfister, S.M. (2012). Medulloblastomics: the end of the beginning. *Nat. Rev. Cancer* 12, 818–834.

- Plath, K., Mlynarczyk-Evans, S., Nusinow, D.A., and Panning, B. (2002). Xist RNA and the mechanism of X chromosome inactivation. *Annu. Rev. Genet.* *36*, 233–278.
- Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G.R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011). Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. *Nature* *475*, 101–105.
- Richter, J., Schlesner, M., Hoffmann, S., Kreuz, M., Leich, E., Burkhardt, B., Rosolowski, M., Ammerpohl, O., Wagener, R., Bernhart, S.H., et al.; ICGC MMML-Seq Project. (2012). Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat. Genet.* *44*, 1316–1320.
- Schuster-Böckler, B., and Lehner, B. (2012). Chromatin organization is a major influence on regional mutation rates in human cancer cells. *Nature* *488*, 504–507.
- Stamatoyannopoulos, J.A., Adzhubei, I., Thurman, R.E., Kryukov, G.V., Mirkin, S.M., and Sunyaev, S.R. (2009). Human mutation rate associated with DNA replication timing. *Nat. Genet.* *41*, 393–395.
- Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009). The cancer genome. *Nature* *458*, 719–724.
- Tort, F., Bartkova, J., Sehested, M., Orntoft, T., Lukas, J., and Bartek, J. (2006). Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. *Cancer Res.* *66*, 10258–10263.
- Weischenfeldt, J., Simon, R., Feuerbach, L., Schlangen, K., Weichenhan, D., Minner, S., Wuttig, D., Warnatz, H.-J., Stehr, H., Rausch, T., et al. (2013). Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. *Cancer Cell* *23*, 159–170.
- Weisse, K., Lehmann, I., Heroux, D., Kohajda, T., Herberth, G., Röder, S., von Bergen, M., Borte, M., and Denburg, J. (2012). The LINA cohort: indoor chemical exposure, circulating eosinophil/basophil (Eo/B) progenitors and early life skin manifestations. *Clin. Exp. Allergy* *42*, 1337–1346.
- Welch, J.S., Ley, T.J., Link, D.C., Miller, C.A., Larson, D.E., Koboldt, D.C., Wartman, L.D., Lamprecht, T.L., Liu, F., Xia, J., et al. (2012). The origin and evolution of mutations in acute myeloid leukemia. *Cell* *150*, 264–278.
- Zhang, J., Benavente, C.A., McEvoy, J., Flores-Otero, J., Ding, L., Chen, X., Ulyanov, A., Wu, G., Wilson, M., Wang, J., et al. (2012). A novel retinoblastoma therapy from genomic and epigenetic analyses. *Nature* *481*, 329–334.